Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own fat cells help heal damaged lungs?

NCT ID NCT02946658

Disease control Sponsor: Healeon Medical Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether stem cells taken from a person's own belly fat can safely help treat chronic lung diseases like COPD. About 100 adults with moderate to severe COPD will receive their own processed cells through an IV. The main goal is to check safety and see if lung function improves.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stem cells from the patient's own fat tissue (adipose-derived stem/stromal cells)
What this could lead to
If it works, this could point toward a treatment that improves lung function and breathing in people with chronic lung disease.
What could go wrong
This is an early Phase 1/2 trial with only 100 participants, so results may not apply to everyone. The study is currently suspended, and risks include unknown side effects from the procedure or cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2016

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prior Diagnosis of moderate to severe COPD * GOLD II a, III, IV Exclusion Criteria: * Pregnant or Lactating Females * Life expectancy of \< 3 months due to concomitant illnesses * Exposure to any investigational drug or procedure with 1 month prior to study entry or enrollment in concurrent study which may interfere with interpretation of study results * Illness which, in investigators judgement, may interfere with the patient' ability to comply with protocol, compromise patient safety, ability to provide informed consent to study, or interfere with interpretation of study outcomes * Subjects on chronic immunosuppressive or chemotherapeutic medications * Known drug or alcohol dependence or other factors which may interfere with study conduct or interpretation of result or in the opinion of investigator are not suitable to participate. * Subjects with documented Alpha-1 Antitrypsin Deficiency (Inherited lung and liver disorder) * Unwilling or not competent to understand and execute an informed consent agreement * Patients positive for Hepatitis (Hepatitis A history excepted)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease lung disorder pulmonary emphysema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Global Alliance for Regenerative Medicine (GARM)

    Roatán, HN, Honduras

  • Regenevita LLC

    Stevensville, Montana, 59870, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.